ライフサイエンスコーパス: C5b-9

1 he cytolytic membrane attack complex (MAC or C5b-9).

2 3/7) and lung deposition of collagen and C' (C5b-9).

3 ore formation by the membrane attack complex C5b-9.

4 gG3kappa deposits together with C3, C1q, and C5b-9.

5 being associated with substantial levels of C5b-9.

6 significantly more lytic activity than with C5b-9.

7 deposition of C4 and C3 and the formation of C5b-9.

8 r LY294002 reversed the protective effect of C5b-9.

9 did not affect C5b-7 uptake or hemolysis by C5b-9.

10 godendrocytes was significantly increased by C5b-9.

11 is of oligodendrocytes was also inhibited by C5b-9.

12 ace and are abnormally sensitive to lysis by C5b-9.

13 blocks in vitro generation of C3a, C5a, and C5b-9.

14 for deposition of C3 fragments and activated C5b-9.

15 f the potent proinflammatory factors C5a and C5b-9.

16 minal complement activation products C5a and C5b-9.

17 illaries but only a few of these reacted for C5b-9.

18 as generation of the membrane attack complex C5b-9.

19 ntly increased serum levels of C3a, C5a, and C5b-9.

20 netic properties differed for C9 addition to C5b-9(1) (0.27 s(-1) at 25 degrees C, 21 kcal/mol), indi

21 2 and 15 times that of C9 for the C5b-8 and C5b-9(1) complexes, respectively.

22 Assembly of monomeric FITC-C9 with C5b-8 or C5b-9(1) produced a substantial decrease in fluorescence

23 Clusterin binding to C5b-8 and C5b-9(1) was reversible with affinities that were 2 and

24 ase of RBC-derived microvesicles coated with C5b-9, a process that was inhibited by EDTA, in the abse

25 r, factor D inhibition prevents both C3c and C5b-9 accumulation.

26 C5b-9 activates Akt as shown by in vitro kinase assay an

27 This indication of physiologic levels of C5b-9 activation in normal kidney potentially explains t

28 n was mediated by both surface-bound C3b and C5b-9 activity.

29 odels, or mouse models that lack significant C5b-9 activity.

30 However, C5b-9 alone did not initiate proliferation or commenceme

31 d the terminal complement complex neoantigen C5b-9 along the outer surface of the Schwann cells.

32 capillary deposition of C1q, C3, C4d, and/or C5b-9 along with immunoglobulin, including IgG, with var

33 C5b-9 also down-regulated the expression of FasL and the

34 Complement C5b-9 also induced parallel activation of GEF-H1 and Rho

35 infected patients displayed a lower level of C5b-9 and a reduced antimicrobial effect on model organi

36 Clusterin inhibited C9 assembly on C5b-8 and C5b-9 and also bound to C5b-7 to prevent membrane attach

37 rine C3d was better than C3, plasma C4d, Bb, C5b-9 and anti-double-stranded DNA antibody in distingui

38 Deposition of iC3b and C5b-9 and bacterial killing occurred when bacteria were

39 Furthermore, glomerular fixation of C5b-9 and C3 was diminished by MC5R agonism but enhanced

40 Immunofluorescence showed that C5b-9 and C4d deposition occurred linearly along the epi

41 C5b-9 and C4d were almost universally deposited linearly

42 Both C5b-9 and C5b-7, but not C5b6, increased Raf-1 kinase ac

43 as accommodated grafts had low deposition of C5b-9 and high expression of CD59.

44 erial and venous microthrombi, deposition of C5b-9 and MASP2 (representative of alternative and lecti

45 ro after injury that was induced by sublytic C5b-9 and PA.

46 correlated with staining for complement (C3, C5b-9) and IgG1 isotype in glomerular immune deposits.

47 Complement activation (C3, C5b-9) and immune cell infiltration (Iba1, CD68) were ob

48 MAC is composed of C5b to C9 (C5b-9) and mediates cell lysis of invaded pathogens.

49 s (C3a and C5a) and membrane attack complex (C5b-9) and opsonizes targeted cells.

50 od cell lysis via membrane attack complexes (C5b-9) and the formation of chemoattractant C5a.

51 5aR, local and systemic induction of soluble C5b-9, and amplified expression of C3aR/C5aR in lesions.

52 nce showed no significant reduction in C3 or C5b-9, and electron microscopy revealed persistent depos

53 ns were analyzed for deposition of C1q, C4d, C5b-9, and immunoglobulin (IgG, IgM, and IgA).

54 tion of exogenous antigen, mouse IgG, C3 and C5b-9, and podocyte injury.

55 nase and Akt activities were also induced by C5b-9, and the phosphatidylinositol 3-phosphate kinase i

56 position of the complement components C4 and C5b-9, and this correlated with an increase in bacterici

57 C3 fragments and C5b-9 are deposited on TF1PIGAnull target cells, and com

58 C3 and C5b-9 are found in immune deposits of IMN kidney biopsy

59 The effects of C5b-9 are mediated via signaling pathways, including cal

60 We show that the terminal complement complex C5b-9 assembles rapidly on the basal surface of cultured

61 onents through its ATPase domain and inhibit C5b-9 assembly and stability.

62 mbrane C5b-9 assembly, and the prevention of C5b-9 assembly on endothelial cells via upregulation of

63 t protect self cells from C3b deposition and C5b-9 assembly on their surfaces.

64 The impact on C5b-9 assembly was the most potent.

65 stream of C3a and C5a receptors and membrane C5b-9 assembly, and the prevention of C5b-9 assembly on

66 ERK1 activity was 2-fold increased by C5b-9 at 2 min and by C5b-7 at 10 min, over the C5b6 lev

67 onstrated co-localization of Cav-1-EGFP with C5b-9 at the plasma membrane, in early endosomes, at the

68 ndicated by depleted C4 and elevated soluble C5b-9, Ba, and Bb antigens.

69 n exposed to sublytic (<5% lysis) amounts of C5b-9, become activated.

70 tor expression and for IgG, IgM, C3, C4, and C5b-9 binding after incubation in 100% human serum.

71 miR-200b/c overexpression reduced C5b-9 binding and enhanced its release from the cells an

72 e evaluated for the presence of C4d, Bb, and C5b-9 by quantitative microassay plate enzyme immunoassa

73 Preventing the endocytosis of C5b-9 by RPE cells led to structural defects in mitochon

74 rface and that processing and destruction of C5b-9 by this route are essential for RPE cell survival.

75 sy specimen showed granular staining for C3, C5b-9, C1q, and IgG3kappa; electron microscopy revealed

76 ease activity at subsequent visits than were C5b-9, C3, and C4.

77 ase activity at all 3 visits than were serum C5b-9, C3, and C4.

78 pC-A, -B, and -C changed soluble fluid-phase C5b-9, C3bBbP, and C3bc to the same extent as CpG-A, -B,

79 ed for complement activation products (ELISA-C5b-9, C4d, activated C1, and C5a) and major complement-

80 Levels of C5b-9, C4d, and activated C1 were significantly increase

81 Tissue sections were stained for C5b-9, C4d, and laminin.

82 EC, a major downstream target of PI3K, or if C5b-9 can induce the migration of AEC, a critical step i

83 were treated with ICs together with nonlytic C5b-9, changes associated with T cell activation by poss

84 In support of this idea, we observed that C5b-9 colocalizes with the early endosome marker EEA1 an

85 gs demonstrated increased immunostaining for C5b-9 compared with nontransplanted controls, confirming

86 Assembly of the terminal C5b-9 complement complex and activation of the complemen

87 Activation of complement and assembly of the C5b-9 complement complex have been implicated in the pre

88 plement-derived peptides and of the terminal C5b-9 complement components that comprise the membrane a

89 d for vascular deposits of IgG, IgM, and the C5b-9 complement membrane attack complex.

90 olytic proteolytically activated form of C5 (C5b)-9 complex.

91 Soluble C5b-9 complex concentrations in zymosan-activated human

92 or LP activation resulting in reduced C4 and C5b-9 complex deposition.

93 The C5b-9 complex is the executioner of CDC.

94 s, Factor X, and complement proteins (C5 and C5b-9 complex) were identified in all drusen phenotypes.

95 Sections were immunostained with anti-human C5b-9 complex, the terminal complement cascade (TCC) neo

96 generation of the anaphylotoxin C3a and the C5b-9 complex.

97 avage of C5, and production of the cytolytic C5b-9 complex.

98 n of the anaphylatoxin C5a and the cytolytic C5b-9 complex.

99 sly shown by us to bind to components of the C5b-9 complex.

100 CDC, probably by facilitating purging of the C5b-9 complexes by endocytosis and exo-vesiculation.

101 Thus, cells actively remove the C5b-9 complexes from their plasma membrane by endocytosi

102 We have previously shown that sublytic C5b-9 complexes, through posttranslational regulation of

103 tored when properdin was added together with C5b-9 components (step 2), thus after convertase formati

104 C5b-9 components of complement were present diffusely in

105 hich stain for IgG, C3, and membrane attack (C5b-9) components of complement and (2) the excretion of

106 Zymosan profoundly elevated soluble C5b-9 concentrations in human sera in vitro.

107 L-10, and complement membrane attack complex C5b-9 concentrations using enzyme-linked immunoassay.

108 C5b-9-dependent adhesion was blocked by neuraminidase tr

109 <0.0003) and the amount of C1q, C3, C4d, and C5b-9 deposition (P <0.05).

110 ivation shows an inverse correlation between C5b-9 deposition and the level of mortalin in the cell.

111 of the transplanted lung revealed decreased C5b-9 deposition compared with controls.

112 cal staining confirmed a reduction in C3 and C5b-9 deposition in Crry-transfected cells.

113 C5b-9 deposition occurred in 13 (87%) of 15 patients wit

114 hemolysis and inhibited both C3 fragment and C5b-9 deposition on ADP-activated HMEC-1 cells, an exper

115 rong C1q and C3b, but relatively low C4b and C5b-9 deposition on analyzed cell lines.

116 rs of the hybrid CFHR1/CFH gene induced more C5b-9 deposition on endothelial cells than control serum

117 Decreased C3bi and C5b-9 deposition on RBCs and neutrophils was documented

118 ith local complement activation with C3b and C5b-9 deposition on the mesangial cell surface in vitro

119 occurred despite a significant reduction in C5b-9 deposition per lesion unit area, suggesting the cr

120 Increased C5b-9 deposition was evident by confocal microscopy and

121 Activated C5b-9 deposition was seen adjacent to tumor nests in a m

122 C3 and C5b-9 deposition were demonstrated in the renal cortex o

123 A positive mHam (and corresponding C5b-9 deposition) were present in 85.7% of catastrophic

124 f kidney dysfunction, glomerulosclerosis, C3/C5b-9 deposition, and reduced circulating C3 compared wi

125 0% human plasma induced complement C3b/c and C5b-9 deposition, cellular activation and coagulation ac

126 erived anti-beta2GPI antibodies also induced C5b-9 deposition, which was blocked completely by an ant

127 Damaged glomeruli showed IgM, IgG, C4d, and C5b-9 deposition.

128 n the graft were responsible for the lack of C5b-9 deposition.

129 irment of complement regulation, measured as C5b-9 deposition.

130 Cs) and neutrophils were stained to evaluate C5b-9 deposition.

131 n (IgM and IgG) and complement (C3, C4d, and C5b-9) deposition, as well as with subsequent increases

132 sies were grouped according to the amount of C5b-9 deposits (no or low n=15/42, 36%; intermediate n=1

133 Eighty-eight percent of biopsies showed C5b-9 deposits in glomeruli.

134 In this study, we show glomerular C5b-9 deposits in the renal biopsy of a child with EHEC-

135 culizumab, whereas serum-induced endothelial C5b-9 deposits normalized after treatment, paralleled or

136 Using assays of ex vivo serum-induced C3 and C5b-9 deposits on endothelial cells, we documented that

137 ot serum from remission, caused wider C3 and C5b-9 deposits than control serum on unstimulated human

138 lomerulonephritis, serum-induced endothelial C5b-9 deposits were normal.

139 C5b-9 deposits were present in 78.6% of TMA cases and in

140 mutation carriers, induced excessive C3 and C5b-9 deposits.

141 dy, we assessed the formation and release of C5b-9 during early reperfusion in clinical kidney transp

142 ese data suggest that sublytic deposition of C5b-9 during hyperacute rejection results in the express

143 significantly inhibited formation of C3a and C5b-9 during SECC.

144 These C5b-9 effects were reversed by PI3K inhibitor LY294002.

145 Cells protect themselves from CDC by C5b-9 elimination, a process involving the mitochondrial

146 lasmid or by treatment with Dynasore reduced C5b-9 endocytosis and enhanced CDC.

147 a dominant negative plasmid had no effect on C5b-9 endocytosis and on cell death.

148 C5b-9 endocytosis was also disrupted by pretreatment of

149 lasmid sensitized cells to CDC and inhibited C5b-9 endocytosis.

150 C5b-9 endothelial deposits might help monitor eculizumab

151 iR-200 (b and c), suggesting that complement C5b-9 exerts a feedback-regulatory effect on these miRNA

152 of Cav-1 and cholesterol depletion abrogated C5b-9 exo-vesiculation, whereas, over-expression of Cav-

153 whereas, over-expression of Cav-1 increased C5b-9 exo-vesiculation.

154 N with intense staining for PLA2R, IgG4, C3, C5b-9, factor B, and properdin and very weak staining fo

155 t activation as measured by soluble terminal C5b-9 formation and C3c deposition on the CC surface.

156 This was demonstrated in vitro by C5b-9 formation and C5a active fragment production in th

157 nteractions, aVn-induced inhibition of lytic C5b-9 formation and of serum killing could be reversed.

158 he tubulointerstitium and that prevention of C5b-9 formation in tubules could slow the deterioration

159 These findings suggest that C5b-9 formation resulting from proteinuria contributes t

160 sulting in decreased C4b, iC3b, and terminal C5b-9 formation.

161 eases in C3b deposition, C3a generation, and C5b-9 formation.

162 Membrane attack complex (C5b-9) formation and Gram's staining revealed that compl

163 The C5b-9 forms lytic or non lytic pores in the cell membran

164 When cells were exposed to C5b-9, GTP-bound Ras in anti-C5b-9 immunoprecipitates wa

165 k complex, composed of complement components C5b-9, has been connected to lytic cell death and implic

166 were exposed to C5b-9, GTP-bound Ras in anti-C5b-9 immunoprecipitates was increased 3.2-fold at 2 min

167 ctivation, as evidenced by the generation of C5b-9 immunoreactive terminal complement complexes in as

168 sed IL-1b, CCL2, and CFB as well as enhanced C5b-9 immunostaining were observed by confocal microscop

169 CD14), TF, and activated complement iC3b and C5b-9 in a human brain thrombus.

170 not reflected by renal tissue deposition of C5b-9 in biopsies taken 45 min after reperfusion.

171 To elucidate the role of C5b-9 in complement-mediated effects on renal tubular ce

172 esults not only confirm the critical role of C5b-9 in complement-mediated hemolysis and but also high

173 ts in all cases, suggesting a long t(1/2) of C5b-9 in extracellular matrix.

174 Normal renal biopsies stained positive for C5b-9 in glomeruli, tubular basement membranes, and vess

175 and but also highlight the critical role of C5b-9 in inflammasome activation.

176 All rfaH and lpp mutants bound C3b and C5b-9 in large quantities.

177 We first assembled the C5b-9 in situ on the membrane and observed its assembly

178 , with CD59 functioning by binding C5b-8 and C5b-9 in the assembling complex.

179 C9(-/-)) for directly dissecting the role of C5b-9 in the pathogenesis of human diseases.

180 eye, as evidenced by increased deposition of C5b-9 in the retinal pigment epithelium (RPE) and choroi

181 Fas pathway in OLG apoptosis and the role of C5b-9 in this process.

182 C5 inhibition prevents accumulation of C5b-9 in vitro but does not prevent upstream complement

183 ular deposition of IgG (mostly IgG4, C3, and C5b-9) in a granular pattern typical of MN.

184 ntiplasmin [PAP]), and complement (C3b, C5a, C5b-9) in baboons infused with factor Xa (FXa) and phosp

185 on and sublytic terminal complement complex (C5b-9) in CD4(+) T-cell responses is not investigated.

186 e of the complement membrane attack complex (C5b-9) in mediating hyperacute rejection has been demons

187 deposition of membrane attack complex (MAC, C5b-9) in nerve membranes.

188 th more intense complement staining (C3d and C5b-9) in the vascular pole in kidneys that developed DG

189 glomerular deposition of autologous IgG and C5b-9, in parallel with higher circulating levels of aut

190 which blocks the formation of human C5a and C5b-9, in preventing the immune-mediated motor neuropath

191 time an important role for C6, and therefore C5b-9, in the pathogenesis of nonimmunologic tubulointer

192 Sublytic C5b-9 increased extracellular signal-regulated kinase-1

193 activation are potential mechanisms by which C5b-9 increases survival of oligodendrocyte in vitro and

194 r the activation products iC3b, C4d, Bb, and C5b-9 indicated that ABri and ADan are able to fully act

195 Exposure to C5b-9 induced an inhibition of caspase-8 activation, Bid

196 Furthermore, ICs and nonlytic C5b-9 induced T cell proliferation and IFN-gamma product

197 C5b-9-induced cell cycle activation was inhibited by pre

198 ts that the PI3K/Akt pathway is required for C5b-9-induced cell cycle activation.

199 -specific inhibitor PD 098,059 abolished the C5b-9-induced DNA synthesis.

200 A major finding was that sublytic C5b-9-induced injury caused an increase in DNA damage in

201 ugmented the DNA damage response to sublytic C5b-9-induced injury.

202 passive Heymann nephritis (PHN)), complement C5b-9-induced proteinuria was associated with the activa

203 In this study, we show that C5b-9 induces AEC proliferation and migration and also a

204 These results show that sublytic C5b-9 induces DNA damage in vitro and in vivo and may ex

205 We have shown that C5b-9 induces proliferation and activates phosphatidylin

206 lytic activation of complement, particularly C5b-9, induces cell cycle progression in aortic smooth m

207 erimental membranous nephropathy, complement C5b-9-induces glomerular epithelial cell (GEC) injury an

208 C5b-9 inhibited the mitochondrial pathway of apoptosis i

209 rs via BCL6, but increased the expression of C5b-9 inhibitor CD59.

210 sisting of C5b, C6, C7, C8, and C9 proteins (C5b-9) inhibits caspase-3 activation and apoptotic death

211 Here we induced sublytic C5b-9 injury in vitro by exposing cultured rat podocytes

212 a subset of Abeta42 plaques and, along with C5b-9 IR, was localized to dystrophic neurites in a subs

213 increase in DNA synthesis, however, sublytic C5b-9 is associated with a delay in G(2)/M phase progres

214 ffector products, cleaved C3, cleaved C5, or C5b-9, is responsible.

215 lial cell (GEC) injury induced by complement C5b-9 leads to proteinuria.

216 C3 level in 22/50 (43%) and elevated soluble C5b-9 level in 27/34 (79%) patients.

217 tistical significance (p = .090) and soluble C5b-9 levels were significant only for dose (p = .023).

218 C5b-9 levels were significantly increased in NP tissue c

219 nt and correlated with plasma C3 and soluble C5b-9 levels.

220 ases in soluble terminal complement complex (C5b-9) levels after challenge with lethal Stx1 (n = 6) o

221 luble terminal complement complex formation (C5b-9) locally and active TGF-beta1 systemically.

222 easurements of complement biomarkers C5a and C5b-9 may confirm the diagnosis of aHUS and differentiat

223 data indicate that cell cycle activation by C5b-9 may involve p34CDC2 activity through RGC-32.

224 ediated injury, while CD59 limits consequent C5b-9-mediated cell damage.

225 deposits initiate complement activation and C5b-9-mediated damage of the overlying podocyte.

226 Thus, GEC CYP2B1 contributes to complement C5b-9-mediated injury and plays an important role in the

227 n, was significantly decreased by complement C5b-9-mediated injury but was preserved in CYP2B1-silenc

228 lternative complement pathway activation and C5b-9-mediated tubular injury can occur in MN and other

229 d glycoprotein CD59 inhibits assembly of the C5b-9 membrane attack complex (MAC) of human complement.

230 s as the principle cellular inhibitor of the C5b-9 membrane attack complex (MAC) of human complement.

231 bits the activity of the C9 component of the C5b-9 membrane attack complex (MAC), thereby protecting

232 suggesting that complement activation to the C5b-9 membrane attack complex had a casual role in renal

233 At a sublytic dose, the C5b-9 membrane attack complex protects oligodendrocytes

234 Quantification of the binding of the C5b-9 membrane attack complex to cells during complement

235 and mediate formation of the proinflammatory C5b-9 membrane attack complex, in functionally active fo

236 nd attenuated deposition of C3 fragments and C5b-9 membrane attack complexes on cell surfaces.

237 IR for C4d and C5b-9 (membrane attack complex, MAC) was observed in sma

238 IgG-kappa in the same distribution as C3 and C5b-9, mimicking monoclonal Ig deposition disease (MIDD)

239 se the possibility that ICs and the nonlytic C5b-9 modulate T cell-mediated responses in systemic lup

240 Samples were assayed for C3a and C5b-9, monocyte activation (CD11b upregulation), PMN act

241 of the terminal complement products C5a and C5b-9 occur only on the VWF-A2 domain.

242 he formation of the membrane attack complex (C5b-9 of complement).

243 bly of the terminal membrane attack complex (C5b-9) of complement.

244 C5b-9 often colocalized with von Willebrand factor in lu

245 igodendrocytes, and the inhibitory effect of C5b-9 on apoptotic process were investigated.

246 C5 inhibition prevents the accumulation of C5b-9 on cells, but not C3c; however, factor D inhibitio

247 e lysis and deposition of complement C3b and C5b-9 on endothelial cells and platelets, we now show th

248 complement complexes (TCC) C5b-7, C5b-8, and C5b-9 on target cells during acute and chronic inflammat

249 cytic pathway to prevent the accumulation of C5b-9 on the cell surface and that processing and destru

250 ade in human plasma and caused deposition of C5b-9 on the platelet surface.

251 in oligodendrocyte apoptosis and the role of C5b-9 on this process.

252 he cytolytic membrane attack complex (MAC or C5b-9) on host cell membranes.

253 neration of lytic membrane attack complexes (C5b-9) on surfaces of pathogens.

254 ization of C9 to the C5b-8 complex forms the C5b-9 (or MAC).

255 0001) as was the degree of C1q, C3, C4d, and C5b-9 ( P<0.05).

256 contrast, significantly lower deposition of C5b-9 (P < 0.0001), fibrin (P = 0.009), and diminished e

257 These studies demonstrate that C5b-9 plays an important role in hyperacute rejection of

258 To investigate what role C5b-9 plays in spinal cord injury and recovery, we gener

259 n of terminal complement components (C5a and C5b-9) prevents platelet and neutrophil (PMN) but not mo

260 lement-dependent cytotoxicity (CDC) with its C5b-9 protein complex that is assembled on cell surfaces

261 ne of 50 dermatomyositis specimens contained C5b-9 reactive endomysial microvessels but none of these

262 Reduction in glomerular C3d and C9/C5b-9 reactivity was observed after daily administration

263 and cell activation properties, both C5a and C5b-9 regulate the downstream inflammatory cascade, whic

264 Our data indicate that C5b-9 regulation of the cell cycle activation in AEC thr

265 Further investigation of the process of C5b-9 removal by exo-vesiculation demonstrated that inhi

266 Assembly of sublytic C5b-9 resulted in inhibition of caspase-3 activation.

267 There was no release of soluble C5b-9 (sC5b-9) from living donor kidneys, nor was there

268 y assess the prognostic value of C3, soluble C5b-9 (sC5b-9), C3 nephritic factor, and rare disease-pr

269 C4d and C5b-9 should be investigated as possible diagnostic biom

270 ments with the complement components C3b and C5b-9 showed that the underlying mechanism of evasion va

271 myopathologic findings are active myopathy, C5b-9 staining of endomysium, focal perivascular and per

272 inhibit complement activation at the C3 and C5b-9 step, respectively.

273 sphorylated at Ser-256 and inactivated after C5b-9 stimulation as shown by a decrease in DNA binding

274 BL), and shared neurotoxic effectors C3b and C5b-9 terminal C complex were significantly higher and t

275 DE levels of C4b, factor D, Bb, MBL, C3b and C5b-9 terminal C complex, and depressions of CR1 and CD5

276 mplement activation and deposition of C3 and C5b-9 that can cause tubule-interstitial damage, further

277 ation of the roles of the C5a-C5aR1 axis and C5b-9 (the membrane attack complex) on kidney disease.

278 Deposition of complement components C3 and C5b-9 (the membrane attack complex), however, was reduce

279 indicating activation of complement (C4d and C5b-9), the complement inhibitor apolipoprotein J (apo J

280 previously shown that generation of sublytic C5b-9, the membrane attack complex of complement, induce

281 In this study, we observed deposition of C5b-9, the terminal product of complement activation, in

282 wing the insertion of sublytic quantities of C5b-9, there is an increase in signaling pathways and gr

283 These data suggest that C5b-9 through PI3K signaling can rescue OLG from Fas-med

284 rocyte apoptosis is, therefore, inhibited by C5b-9 through post-translational regulation of Bad.

285 cell killing) and cell-surface deposition of C5b-9 to test the hypothesis that complement activation

286 thresholds (Cts), blood smears, and soluble C5b-9 values were analyzed with clinical data.RESULTSTwe

287 presence of the dynamin inhibitor dynasore, C5b-9 was almost completely retained at the cell surface

288 ozen section, human IgG and IgM, C3, C4, and C5b-9 was deposited on islets with increased intensity i

289 osition of complement components C3, C6, and C5b-9 was enhanced on the surface of the CspA mutant com

290 ted in the diabetic retinas, suggesting that C5b-9 was generated via the alternative pathway, the spo

291 ing of C1q to RGC and accumulation of C3 and C5b-9 was investigated using immunohistochemical and pro

292 by C3d deposition but deposition of C5b and C5b-9 was limited.

293 Complement terminal pathway fraction C5b-9 was localized in injured arteries.

294 luding plasma Bb, serum Wieslab, and urinary C5b-9 was observed.

295 Moreover, C5b-9 was present in >75% of the TMA samples, suggesting

296 tivation [C3a, C5a, and terminal C' complex (C5b-9)] was attenuated in il17a(-/-) mice, and IL-17A ne

297 inal complement complex, also referred to as C5b-9, we incubated these immune reactants with peripher

298 f C4d, mannose-binding lectin, C1q, IgM, and C5b-9 were scored in the glomeruli, peritubular capillar

299 and terminal complement activation (C5a and C5b-9) were increased in the plasma of these 19 patients

300 d grafts had deposition of IgM, IgG, C3, and C5b-9 with low expression of CD59, whereas accommodated